welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
source: Proceedings of the National Academy of Sciences of the United States of America
year: 2015
authors: Hathout Y, Brody E, Clemens PR, Cripe L, DeLisle RK, Furlong P, Gordish-Dressman H, Hache L, Henricson E, Hoffman EP, Kobayashi YM, Lorts A, Mah JK, McDonald C, Mehler B, Nelson S, Nikrad M, Singer B, Steele F, Sterling D, Sweeney HL, Williams S, Gold L
summary/abstract:Serum biomarkers in Duchenne muscular dystrophy (DMD) may provide deeper insights into disease pathogenesis, suggest new therapeutic approaches, serve as acute read-outs of drug effects, and be useful as surrogate outcome measures to predict later clinical benefit. In this study a large-scale biomarker discovery was performed on serum samples from patients with DMD and age-matched healthy volunteers using a modified aptamer-based proteomics technology. Levels of 1,125 proteins were quantified in serum samples from two independent DMD cohorts: cohort 1 (The Parent Project Muscular Dystrophy-Cincinnati Children’s Hospital Medical Center), 42 patients with DMD and 28 age-matched normal volunteers; and cohort 2 (The Cooperative International Neuromuscular Research Group, Duchenne Natural History Study), 51 patients with DMD and 17 age-matched normal volunteers. Forty-four proteins showed significant differences that were consistent in both cohorts when comparing DMD patients and healthy volunteers at a 1% false-discovery rate, a large number of significant protein changes for such a small study. These biomarkers can be classified by known cellular processes and by age-dependent changes in protein concentration. Our findings demonstrate both the utility of this unbiased biomarker discovery approach and suggest potential new diagnostic and therapeutic avenues for ameliorating the burden of DMD and, we hope, other rare and devastating diseases.
organization: Children's National Medical Center, USA; SomaLogic, USA; University of Pittsburgh, USA; The Ohio State University, USA; Parent Project Muscular Dystrophy, USA; University of California Davis School of Medicine, USA; Indiana University School of Medicine, USA; Cincinnati Children's Hospital Medical Center, USA; University of Calgary, Alberta Children's Hospital, Canada; University of Colorado Denver, USA; University of Florida College of Medicine, USADOI: 10.1073/pnas.1507719112
read more full text source
rareRelated
-
Magnetic Resonance Imaging and Biomarkers for Muscular DystrophyThe purpose of this research study is to...
-
Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Musc...Catabasis Pharmaceuticals, Inc. (NASDAQ:...
-
Native T1 values identify myocardial changes and stratify disease severity in patients with Duchenne muscular dystro...Background: Duchenne muscular dystrophy...
-
Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large Duchenne muscular dystrophy c...Objective: The aim of this study was to...
-
A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular DystrophyTo characterize the natural history and ...
-
Non-invasive Imaging of Muscle Structure in Duchenne Muscular Dystrophy Using Multispectral Optoacoustic TomographyThis pilot study aims to assess subcellu...
-
2D Strain Evaluation: Children With Duchenne Muscular Dystrophy Versus Healthy ChildrenCompare systolic function of left ventri...
-
Duchenne muscular dystrophy: How muscle cells journey to the dark sidePromoting repair of dystrophic muscles i...
-
Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophyObjective: To explore the value of nucl...